Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.

[1]  Bruno Sangro,et al.  Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives , 2013, Hepatology.

[2]  Carlo Morosi,et al.  Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: A phase 2 study , 2013, Hepatology.

[3]  K. Öberg.  Implications for Clinical Practice and Trial Design , 2012 .

[4]  J. Bruix,et al.  Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.

[5]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[6]  D. Sze,et al.  Research reporting standards for radioembolization of hepatic malignancies. , 2011, Journal of vascular and interventional radiology : JVIR.

[7]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[8]  J. Prieto,et al.  Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages , 2011, Annals of Surgical Oncology.

[9]  J. Ertle,et al.  Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival , 2010, Hepatology.

[10]  J. Trinchet,et al.  Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail. , 2010, Journal of hepatology.

[11]  G. Abou-Alfa,et al.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ding‐Shinn Chen,et al.  Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. , 2009, European journal of cancer.

[13]  G. Abou-Alfa.  Hepatocellular carcinoma: molecular biology and therapy. , 2006, Seminars in oncology.

[14]  C. Georgiades,et al.  Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[15]  Kenneth G. Thurston,et al.  Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. , 2006, Journal of vascular and interventional radiology : JVIR.

[16]  Alessandro Vitale,et al.  Prospective validation of the Barcelona Clinic Liver Cancer staging system. , 2006, Journal of hepatology.

[17]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[18]  J. Marrero,et al.  Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.

[19]  W. Chapman,et al.  Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. , 2004, Journal of vascular and interventional radiology : JVIR.

[20]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[21]  M. Abecassis,et al.  AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. , 2003, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[22]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[23]  M. Sherman,et al.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto , 2002, Gut.

[24]  K. Leung,et al.  Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system , 2002, Cancer.

[25]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[26]  T. Aikou,et al.  Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients , 2001, Hepatology.

[27]  F. Farinati,et al.  How should patients with hepatocellular carcinoma be staged? , 2000, Cancer.

[28]  M. Forster,et al.  Key Concepts in Model Selection: Performance and Generalizability. , 2000, Journal of mathematical psychology.

[29]  S. Chevret,et al.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.

[30]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[31]  D. Hosmer,et al.  A comparison of goodness-of-fit tests for the logistic regression model. , 1997, Statistics in medicine.

[32]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[33]  Alvan R. Feinstein,et al.  XVI. The process of prognostic stratification (Part 2) , 1972 .

[34]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. , 2013, Journal of hepatology.

[35]  H. El‐Serag,et al.  Hepatocellular carcinoma. , 2011, The New England journal of medicine.

[36]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[37]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[38]  A. Zwinderman,et al.  Clinical trials are often false positive: a review of simple methods to control this problem. , 2006, Current clinical pharmacology.

[39]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[40]  A. Feinstein.  Clinical biostatistics. XVI. The process of prognostic stratification. 2. , 1972, Clinical pharmacology and therapeutics.

[41]  A. Feinstein.  Clinical biostatistics. XV. The process of prognostic stratification. I. , 1972, Clinical pharmacology and therapeutics.

[42]  C. G. Child,et al.  Surgery and portal hypertension. , 1964, Major problems in clinical surgery.